1 	|BT| (S (PP (IN In) (NP (NN study))) (, ,) (VP (VBD determined) (NP (NP (JJ combined) (NN effect) (NN celecoxib)) (, ,) (NP (NN COX-2) (NN inhibitor)) (, ,)) (PP (IN along) (NP (NP (NP (NN exisulind)) (PRN (-LRB- -LRB-) (NP (NN sulindac) (NN sulfone/Aptosyn)) (-RRB- -RRB-))) (JJ low) (NNS dos) (NN prostate) (NN cancer))))) |ET| |BS|349:D27.505.519.389.310.500 684:D02.065.884.247|ES| 2:1 10:1 14:1 18:1 19:1 75:1 76:1 77:1 131:1 164:1 244:1 380:1 531:1 869:1 1582:1 2653:1 2666:1 2807:1 3575:1 3576:1
1 	|BT| (S (PP (IN In) (NP (NN study))) (, ,) (NP (NP (VBN investigated) (NN role) (NN progastrin)) (VP (VBG regulating) (NP (NNP CSC) (NN phenotype)))) (VP (VBD advanced) (NP (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 15:F01.829.316.616 80:G05.695 556:C11.768.175|ES| 2:1 17:1 18:1 19:1 31:1 131:1 236:1 244:1 403:1 671:1 997:1 2869:1 3577:1
1 	|BT| (S (PP (IN In) (NP (NN view) (JJ strong) (NN association) (NN estrogen))) (, ,) (NP (NP (NN progesterone)) (, ,) (NP (NN prolactin)) (, ,) (NP (NN breast) (NN cancer)) (, ,) (NP (NN PhIP) (NN repertoire)) (NP (JJ hormone-like) (NN activity))) (VP (VBZ provides) (NP (JJ mechanistic) (NN support) (JJ tissue-specific) (NN carcinogenicity) (NN chemical)))) |ET| |BS|98:A10 161:D06.472 279:D27.888.569.100 386:F02.463.425.069 889:D27.505.696.399.472.277 1010:D04.808.745.745.654.829 1023:D06.472.699.322.576.773|ES| 2:1 18:1 19:1 23:1 244:1 399:1 815:1 1298:1 1364:1 1626:1 1890:1 2124:1 2641:1 3168:1 3536:1 3578:1 3579:1 3580:1 3581:1 3582:1 3583:1
1 	|BT| (S (ADVP (FW In) (FW vivo)) (, ,) (NP (NP (NP (NN nimbolide)) (PRN (-LRB- -LRB-) (NP (CD 5) (CD 20) (NN mg/kg) (NN body) (NN weight)) (-RRB- -RRB-))) (, ,) (VP (VBN injected) (ADVP (RB intraperitoneally)) (NP (NN tumor) (NN inoculation))) (, ,)) (ADVP (RB significantly)) (VP (VBD decreased) (NP (NN volume) (JJ colorectal) (NN cancer) (NN xenograft)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 92:E04.936.764 93:A01.941.875 653:C23.888.144 1024:D20.215.894.200 1025:Z01.252.100.450 1026:Z01.252.474.651|ES| 2:1 7:1 10:1 14:1 17:1 18:1 19:1 124:1 202:1 244:1 265:1 378:1 578:1 1870:1 2398:1 2399:1 3584:1 3585:1 3586:1 3587:1 3588:1 3589:1
1 	|BT| (S (NP (VBN Increased) (NN expression) (NN cyclooxygenase-2) (NN protein) (NN rat) (NN hepatocarcinogenesis)) (VP (VBD caused) (ADJP (ADJP (JJ choline-deficient)) (, ,) (NP (NP (NN L-amino) (JJ acid-defined) (NN diet) (JJ chemopreventive) (NN efficacy) (JJ specific) (NN inhibitor)) (, ,) (NP (NN nimesulide)))))) |ET| |BS|7:D12.776 24:D08.811.600.720.750 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 597:D12.125|ES| 2:1 4:1 19:1 61:1 115:1 380:1 540:1 849:1 900:1 1212:1 1946:1 2188:1 2190:1 2191:1 2304:1 2506:1 3183:1 3186:1
1 	|BT| (NP (NP (NN Inhibition) (NN licorice) (NN flavonoid) (NN oil) (NN glutathione) (JJ S-transferase-positive) (NN focus) (JJ medium-term) (NN rat) (NN hepatocarcinogenesis) (NN bioassay))) |ET| |BS|43:F01.145.544 106:E05.091 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 534:D03.383.663.283.266.450 780:D08.811.913.225.500 849:G08.686.785.760.769.490.500 914:L01.178 1027:B01.650.940.800.575.100.401.300 1028:B01.650.940.800.575.100.401.300 1029:D10.627.700 1030:D10.627|ES| 19:1 849:1 900:1 1431:1 1886:1 2614:1 2703:1 2744:1 2931:1 3215:1 3590:1 3591:1
1 	|BT| (S (NP (NN Inhibition) (NN autophagy)) (VP (VBZ potentiates) (NP (JJ antitumor) (NN effect) (NN multikinase) (NN inhibitor) (NN sorafenib) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|43:F01.145.544 104:C04.557.470.200.025.255 390:G04.299.139.399|ES| 19:1 75:1 303:1 304:1 380:1 1317:1 2063:1 2244:1 2499:1 2703:1 3592:1
1 	|BT| (NP (NP (NN Inhibition) (JJ hypoxia-inducible) (NN factor) (NN limit) (NN tumor) (NN progression) (NN mouse) (NN model) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 11:B01.050.150.900.649.865.635.505.500 16:C23.550.291.656 43:F01.145.544 1011:C23.888.852.079 1031:C04.588.274.476.411.307|ES| 7:1 17:1 18:1 19:1 48:1 52:1 72:1 185:1 2703:1 2797:1 3593:1
1 	|BT| (S (NP (NN Inhibition) (NN STAT3) (NN signaling) (NN pathway) (NN nitidine) (NN chloride)) (VP (VBD suppressed) (NP (NN angiogenesis) (NN growth) (JJ human) (JJ gastric) (NN cancer)))) |ET| |BS|43:F01.145.544 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 82:D12.644.360.024.342.300 126:G02.111.087.800|ES| 18:1 19:1 36:1 86:1 102:1 195:1 251:1 307:1 383:1 2502:1 2703:1 2788:1 3594:1
1 	|BT| (S (NP (NP (NN injection) (NN N-diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (VP (VBP initiate) (NP (NN hepatocarcinogenesis)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 226:E02.319.267.530 554:D02.654.442.200|ES| 10:1 14:1 19:1 785:1 900:1 1875:1 3231:1 3595:1
1 	|BT| (FRAG (UCP (NP (JJ Insulin-independent) (NN promotion)) (ADVP (RB chemically)) (NP (VBN induced) (JJ hepatocellular) (NN tumor) (NN development)) (NP (ADJP (RB genetically) (JJ diabetic)) (NN mouse)))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 637:D06.472.699.587.200.500.625|ES| 7:1 19:1 35:1 52:1 303:1 412:1 898:1 2337:1 2581:1 2964:1 3596:1
1 	|BT| (NP (NP (NP (NN Intake) (NNS isoflavones)) (SBAR (S (NP (VBN derived) (NN soybean) (NN product)) (VP (MD may) (VP (VB impact) (NP (NN prostate) (NN cancer) (NN risk)))))))) |ET| |BS|61:E05.318.740.600.800 1001:B01.650.940.800.575.100.401.750 1032:D03.383.663.283.266.450.400|ES| 18:1 19:1 77:1 171:1 491:1 675:1 1721:1 3541:1 3597:1 3598:1 3599:1
1 	|BT| (NP (NP (NP (JJ Interferon-gamma-mediated) (NN hepatocarcinogenesis) (NN mouse)) (VP (VBN treated) (NP (NN diethylnitrosamine))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 52:E02 554:D02.654.442.200 1033:D12.644.276.374.440.893|ES| 19:1 52:1 900:1 1099:1 1952:1 3600:1
1 	|BT| (NP (NP (NN INTERPRETATION)) (: :) (S (S (NP (NN Stimulation) (NN survivin) (NN expression) (NN TCF/beta) (NN catenin)) (VP (MD might) (VP (VB impose) (NP (NN stem) (JJ cell-like) (NN phenotype)) (SBAR (S (NP (JJ colonic) (NN crypt) (NN epithelium) (NN coupling)) (VP (VBD enhanced) (NP (NN cell) (NN proliferation) (NN resistance) (NN apoptosis)))))))) (, ,) (VP (VBP contribute) (NP (JJ molecular) (NN pathogenesis) (JJ colorectal) (NN cancer))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 23:D12.776.091.249 39:G04.299.139.160 46:A03.556.124.526.356 62:A10.272 80:G05.695 183:G04.299.233.750 308:A11.872|ES| 2:1 17:1 18:1 19:1 89:1 94:1 104:1 115:1 161:1 173:1 236:1 299:1 385:1 450:1 501:1 677:1 798:1 1094:1 1106:1 2229:1 2913:1 3601:1 3602:1 3603:1 3604:1 3605:1 3606:1 3607:1
1 	|BT| (NP (NP (NN INTRODUCTION)) (: :) (S (NP (NN Protein) (NN tyrosine) (NN kinase)) (NP (CD 6) (-LRB- -LRB-) (NN PTK6) (-RRB- -RRB-) (JJ non-receptor) (NN tyrosine) (NN kinase)) (ADVP (RB highly)) (VBD expressed) (NP (NP (JJ Human) (NNP Epidermal) (NN Growth) (NN Factor) (CD 2)) (PRN (-LRB- -LRB-) (CC +) (-RRB- -RRB-))) (-LRB- -LRB-) (NP (NP (NN Her2) (PRN (-LRB- -LRB-) (CC +) (-RRB- -RRB-) (-RRB- -RRB-)) (NN breast) (NN cancer))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 923:D06.472.317.350 987:D08.811.913.696.620.682.725.400|ES| 6:1 10:1 14:1 18:1 19:1 23:1 104:1 148:1 444:1 470:1 535:1 626:1 1041:1 1044:1 1219:1 2340:1 2341:1 2911:1 3059:1 3529:1 3608:1 3609:1
1 	|BT| (S (NP (NP (NNP Ling) (NN extract)) (, ,) (NP (JJ high) (NN furanodiene) (NN content)) (, ,)) (VP (VBD showed) (NP (JJ anti-cancer) (NN effect) (NN breast) (NN cancer) (NN cell) (NN vitro)))) |ET| |BS|41:A11|ES| 2:1 18:1 19:1 23:1 75:1 94:1 132:1 178:1 216:1 1112:1 1794:1 2496:1 3610:1 3611:1
1 	|BT| (S (NP (NN Loss) (NN caspase-8)) (VP (VBZ protects) (SBAR (S (NP (NN mouse) (JJ inflammation-related) (NN hepatocarcinogenesis)) (VP (VBZ induces) (NP (JJ non-apoptotic) (NN liver) (NN injury))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 39:G04.299.139.160 242:A03.620 525:C23.550.470 1034:D08.811.277.656.262.500.126.550.800|ES| 19:1 52:1 214:1 836:1 900:1 1788:1 1863:1 2416:1 3612:1 3613:1 3614:1
1 	|BT| (S (NP (NN Loss) (NN metallothionein)) (VP (VBZ predisposes) (NP (NN mouse) (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis) (VBG activating) (NN NF-kappaB) (NN target) (NN gene)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 210:D12.776.260.600 554:D02.654.442.200 777:D12.776.556.670|ES| 9:1 19:1 52:1 160:1 714:1 900:1 1788:1 1948:1 1958:1 2731:1 2732:1
1 	|BT| (S (S (NP (JJ Low) (NN level) (NN Caspase-3)) (VP (VBP predict) (SBAR (S (NP (JJ favourable) (NN response) (JJ 5FU-based) (NN chemotherapy)) (VP (VBD advanced) (NP (JJ colorectal) (NN cancer))))))) (: :) (S (NP (NN Caspase-3) (NN inhibition) (JJ therapeutic) (NN approach)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 43:F01.145.544 52:E02 151:E02.319 333:D01.045 560:D03.383.742.698.875.404 906:D08.811.277.656.262.500.126.350.300|ES| 17:1 18:1 19:1 103:1 104:1 249:1 494:1 495:1 541:1 911:1 997:1 1302:1 2232:1 3190:1 3615:1 3616:1
1 	|BT| (NP (NP (NNP Lupeol) (NN target) (NN liver) (JJ tumor-initiating) (NN cell) (NN phosphatase) (NN tensin) (NN homolog) (NN modulation))) |ET| |BS|242:A03.620 1035:D08.811.277.352.650 1036:A11.872.650|ES| 19:1 94:1 160:1 836:1 1945:1 3617:1 3618:1 3619:1 3620:1 3621:1
1 	|BT| (S (S (NP (NNP Lycopene)) (VP (VBZ modulates) (SBAR (S (NP (NN initiation) (NN N-nitrosodiethylamine)) (VP (VBD induced) (NP (NN hepatocarcinogenesis))))))) (: :) (S (NP (NP (NN study) (JJ chromosomal) (NN abnormality)) (, ,) (NP (NN membrane) (NN fluidity) (JJ antioxidant) (NN defense) (NN system))))) |ET| |BS|554:D02.654.442.200 700:D27.505.519.217 1037:C23.550.210 1038:G01.154.500 1039:C16.131.260|ES| 2:1 19:1 104:1 131:1 412:1 593:1 606:1 637:1 900:1 1002:1 1027:1 1104:1 2521:1 2602:1 2733:1 3622:1 3623:1
1 	|BT| (NP (NP (NNS METHODS) (: :)) (S (NP (DT A) (JJ Solt-Farber) (JJ two-step) (NN test) (NN model) (NN hepatocarcino) (NN genesis)) (VP (VBD established) (S (NP (NP (NP (NP (NP (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (NN 2-acetylaminofluorene)) (PRN (-LRB- -LRB-) (NP (NN AAF)) (-RRB- -RRB-))) (NN rat)) (VP (VBP investigate) (S (VP (VBG modifying) (NP (NP (NP (NN effect) (NN expression) (NN 6-glucosephosphatase)) (PRN (-LRB- -LRB-) (NP (NN G-6-Pase)) (-RRB- -RRB-))) (, ,) (NP (NN succinodehydrogenase) (-LRB- -LRB-) (NN SDH) (-RRB- -RRB-)) (, ,) (NP (NP (NP (NN adenosine) (NN triphosphatase)) (PRN (-LRB- -LRB-) (NP (NN ATPase)) (-RRB- -RRB-))) (JJ N-nitrosodiethylamine-mediated) (NN hepatocarcinogenesis)))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 168:E05.581 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 506:F01.829.263.315 554:D02.654.442.200 767:D02.065.064.150 893:D08.811.277.040.025 894:D08.811.277.040.025 1040:D08.811.277.352.650.225 1041:E01.370.370.380.250|ES| 2:1 10:1 14:1 19:1 69:1 72:1 75:1 104:1 115:1 459:1 565:1 849:1 900:1 1418:1 1875:1 1952:1 2660:1 2762:1 3158:1 3221:1 3271:1 3624:1 3625:1 3626:1 3627:1 3628:1 3629:1 3630:1 3631:1 3632:1 3633:1 3634:1
1 	|BT| (NP (NP (NNS METHODS) (: :)) (S (NP (JJ Male) (ADJP (ADJP (NN C57BL/6) (NN mouse) (NN fed) (NN methionine) (JJ choline-deficient)) (PRN (-LRB- -LRB-) (NP (NN MCD)) (-RRB- -RRB-))) (NN diet)) (VP (VBP induce) (NP (NN steatohepatitis))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 168:E05.581 508:C06.552.241 593:B01.050.050.199.520.520.420 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 663:C16.320.565.398.500.330.500 664:D02.886.030.676|ES| 10:1 14:1 19:1 52:1 104:1 243:1 565:1 1791:1 2050:1 2188:1 2191:1 2192:1 2426:1 2524:1 3635:1
1 	|BT| (S (NP (NNP Methylenetetrahydrofolate) (NN reductase) (NN gene) (NN polymorphism) (NN response) (JJ fluorouracil-based) (NN treatment)) (VP (VBD advanced) (NP (JJ colorectal) (NN cancer) (NN patient)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 50:M01.643 52:E02 307:G05.365.795 333:D01.045 560:D03.383.742.698.875.404 606:D08.811.682.662.290|ES| 9:1 17:1 18:1 19:1 96:1 120:1 494:1 546:1 997:1 1060:1 3636:1 3637:1
1 	|BT| (NP (NP (S (NP (NP (NNS Mice)) (VP (VBG lacking) (NP (NP (NN methionine) (NN adenosyltransferase) (NN 1A)) (PRN (-LRB- -LRB-) (NP (NN MAT1A)) (-RRB- -RRB-))))) (VP (VBD reduced) (NP (NN PHB1) (NN expression)))) (, ,) (JJ impaired) (JJ mitochondrial) (NN function)) (, ,) (VP (ADVP (RB spontaneously)) (VB develop) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 574:D08.811.913.225.650|ES| 2:1 10:1 14:1 19:1 33:1 115:1 303:1 304:1 376:1 441:1 452:1 583:1 648:1 1506:1 1792:1 2003:1 2004:1 2050:1 2051:1 2052:1 2053:1
1 	|BT| (S (VP (VBG Modifying) (NP (NP (NN effect) (NN chitin) (, ,) (NN chitosan) (JJ related) (NN compound) (JJ 2-amino-3,8-dimethylimidazo)) (PRN (-LRB- -LSB-) (NP (NP (NP (NP (JJ 4,5-f) (-RRB- -RSB-) (NN quinoxaline)) (PRN (-LRB- -LRB-) (NP (NN MeIQx)) (-RRB- -RRB-))) (NN rat) (JJ medium-term) (NN hepatocarcinogenesis) (NN model)) (, ,) (NP (JJ post-initiation) (NN effect) (JJ female) (NN rat) (JJ 2-stage) (JJ multi-organ) (NN carcinogenesis) (NN model))))))) |ET| |BS|33:C04.697.098 118:D01.248.497.158.380 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 642:M01.975 849:G08.686.785.760.769.490.500 854:D05.750.078.139.500 855:D05.750.078.139 914:L01.178|ES| 2:1 10:1 14:1 19:1 72:1 75:1 207:1 419:1 849:1 900:1 1373:1 1378:1 1404:1 2433:1 3051:1 3052:1 3215:1 3638:1 3639:1 3640:1 3641:1 3642:1 3643:1 3644:1 3645:1
1 	|BT| (S (VP (VBG Modifying) (NP (NP (NN effect) (NN liver) (NN tumor) (NN promotion) (NN rat)) (VBN subjected) (NN co-administration) (NN indole-3-carbinol) (NN phenobarbital)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 756:D03.383.742.698.253.650 1042:Z01.107.757.284|ES| 7:1 19:1 75:1 836:1 849:1 2337:1 2685:1 3267:1 3638:1 3646:1 3647:1
1 	|BT| (S (NP (NN Monensin)) (VP (VBZ inhibits) (SBAR (S (NP (JJ canonical) (NP (NN Wnt) (NN signaling) (JJ human) (JJ colorectal) (NN cancer) (NN cell))) (VP (VBZ suppresses) (NP (NN tumor) (NN growth) (JJ multiple) (JJ intestinal) (NN neoplasia) (NN mouse))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 11:B01.050.150.900.649.865.635.505.500 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 102:C04.588.274.476.411 122:C14.280.383 1043:D03.383.312.600|ES| 7:1 17:1 18:1 19:1 36:1 52:1 94:1 102:1 109:1 195:1 615:1 640:1 649:1 686:1 877:1 3236:1 3648:1
1 	|BT| (NP (NP (JJ Mycophenolic) (JJ acid-induced) (NN replication) (NN arrest)) (, ,) (NP (NN differentiation) (NN marker) (NN cell) (NN death) (JJ androgen-independent) (NN prostate) (NN cancer) (NN cell) (NN DU145))) |ET| |BS|41:A11 78:G02.111.087.222 134:G04.299.139 852:C04.588.945.440.770.500 1044:D02.241.081.193.678 1045:D23.050.301.264|ES| 2:1 18:1 19:1 77:1 94:1 215:1 231:1 411:1 534:1 602:1 2599:1 3423:1 3520:1 3649:1
1 	|BT| (S (NP (NNP Nestin) (NN silencing)) (VP (ADVP (RB also)) (VP (VBD upregulated) (NP (NP (NN Axin) (, ,) (NP (NP (NN glycogen) (NN synthase) (NN kinase-3) (NN beta)) (PRN (-LRB- -LRB-) (NP (NN GSK-3beta)) (-RRB- -RRB-))) (, ,) (NP (JJ adenomatous) (NN polyposis) (NN coli) (PRN (-LRB- -LRB-) (NP (NN APC)) (-RRB- -RRB-))) (, ,)) (NP (NP (NN peroxisome) (JJ proliferator-activated) (NN receptor) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NN PPARa)) (-RRB- -RRB-))))) (, ,) (VP (VBD downregulated) (NP (NP (NN beta-catenin)) (, ,) (NP (NN c-Myc)) (, ,) (NP (NP (NN cyclin) (NN D)) (NN MMP-7) (NN expression) (NNP CSC)))))) |ET| |BS|3:C04.557.470.035.215.100 21:G05.360.340.024.340.375.249.050 23:D12.776.091.249 536:D12.776.826.239.500 556:C11.768.175 937:D08.811.277.656.300.480.525.700.250 1046:D12.644.360.262.150 1047:D05.750.078.593.540|ES| 2:1 5:1 10:1 11:1 14:1 19:1 57:1 58:1 59:1 60:1 66:1 92:1 100:1 115:1 125:1 186:1 426:1 743:1 824:1 1801:1 1836:1 1887:1 1972:1 2592:1 3577:1 3650:1 3651:1 3652:1 3653:1 3654:1 3655:1
1 	|BT| (NP (NP (NP (NP (NNP Neurotensin) (NN receptor-1)) (PRN (-LRB- -LRB-) (NP (NN NTR-1)) (-RRB- -RRB-))) (NP (JJ overexpressed) (NN colon) (NN cancer) (NN colon) (NN cancer) (NN cell) (NN line)))) |ET| |BS|94:A11.251.210 1048:D12.776.543.750.100.550|ES| 10:1 14:1 18:1 19:1 25:1 94:1 113:1 264:1 3656:1 3657:1 3658:1
1 	|BT| (S (NP (NN Nifuroxazide)) (VP (VBZ induces) (SBAR (S (NP (NN apoptosis)) (VP (VBZ impairs) (NP (JJ pulmonary) (NN metastasis) (NN breast) (NN cancer) (NN model))))))) |ET| |BS|10:A01.236 39:G04.299.139.160 113:C04.697.650 182:A04.411|ES| 18:1 19:1 23:1 72:1 89:1 214:1 806:1 948:1 2729:1 3659:1
1 	|BT| (NP (NP (NP (JJ Nitric) (JJ oxide-releasing) (NN aspirin) (NN indomethacin) (JJ potent) (NN inhibitor) (NN colon) (NN cancer) (JJ azoxymethane-treated) (NN rat)) (: :) (NP (NN effect) (JJ molecular) (NN target)))) |ET| |BS|52:E02 132:D02.172.080 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 795:D03.438.473.420|ES| 18:1 19:1 22:1 75:1 104:1 113:1 160:1 161:1 380:1 849:1 2487:1 2790:1 2791:1 2792:1 2793:1
1 	|BT| (NP (NP (DT No) (VBG Modifying) (NP (NP (NN Effect) (JJ Antioxidant) (NN N-Acetyl-L-Cysteine)) (JJ Fenofibrate-induced) (NNP Hepatocarcinogenesis) (NNS Rats)))) |ET| |BS|13:D01.339.387 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 791:D02.886.030.230.259 916:D02.241.081.114.968.500.625 1049:D27.505.519.217|ES| 19:1 1959:1 3222:1 3638:1 3660:1 3661:1 3662:1 3663:1 3664:1
1 	|BT| (S (NP (JJ Nuclear) (NN Maspin) (NN expression)) (NP (ADJP (RB highly) (JJ predictive)) (NN 5-FU) (NN chemotherapy) (NN response) (NN patient)) (VP (VBD advanced) (NP (NN stage) (NN colon) (NN cancer)))) |ET| |BS|50:M01.643 151:E02.319 560:D03.383.742.698.875.404|ES| 18:1 19:1 113:1 115:1 120:1 494:1 495:1 533:1 626:1 997:1 1129:1 2308:1 2808:1 2809:1
1 	|BT| (S (NP (NN OBJECTIVE) (: :)) (NP (NP (NN Vitamin) (NN D)) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-))) (VP (VBN upregulated) (NP (NP (NN protein) (CD 1) (PRN (-LRB- -LRB-) (NP (NN VDUP1)) (-RRB- -RRB-))) (NP (NP (JJ potent) (NN tumour) (NN suppressor)) (SBAR (WHNP (WP$ whose) (NN expression)) (S (ADVP (RB dramatically)) (VP (VBD reduced) (NP (NP (JJ various) (NN type) (JJ human) (NN cancer)) (, ,) (PP (VBG including) (NP (JJ gastric) (NN cancer))))))))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 206:G05.360.340.024.340.375.249 415:F01.658.500 1050:D12.776.157.125.050.060 1051:D04.808.247.222.159 1052:D12.776.641.750|ES| 2:1 4:1 10:1 14:1 18:1 19:1 22:1 36:1 86:1 98:1 104:1 115:1 125:1 452:1 543:1 561:1 645:1 700:1 862:1 919:1 1011:1 1096:1 1417:1 2592:1 3665:1 3666:1
1 	|BT| (NP (NP (JJ Oncogenic) (NN tumor) (JJ suppressive) (NN role)) (NP (JJ polo-like) (NN kinase) (JJ human) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|8:C04 15:F01.829.316.616 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 279:D27.888.569.100|ES| 7:1 19:1 31:1 36:1 303:1 304:1 470:1 1974:1 2143:1 3667:1
1 	|BT| (NP (NP (CD One) (JJ reasonable) (NN possibility) (JJ attributable) (NN hyperinsulinemia) (JJ compensatory) (JJ obesity-related) (NN insulin) (NN resistance))) |ET| |BS|564:C18.654.726.500 678:C18.452.394.968.500 1053:C18.452.394.968|ES| 19:1 343:1 654:1 1094:1 2364:1 2467:1 3668:1 3669:1 3670:1 3671:1
1 	|BT| (S (NP (PRP$ Our) (NN observation)) (VP (VBP suggest) (NP (NP (JJ chemoprotective) (NN effect) (NN isorhamnetin) (NN colon) (NN cancer)) (VP (VBN linked) (NP (NP (JJ anti-inflammatory) (NN activity) (NN inhibition) (JJ oncogenic) (NN Src) (NN activity) (JJ consequential) (NN loss)) (VP (JJ nuclear) (NP (NP (NN beta-catenin)) (, ,) (NP (NN activity)) (NP (JJ dependent) (NN CSK) (NN expression))))))))) |ET| |BS|23:D12.776.091.249 43:F01.145.544 279:D27.888.569.100 429:N04.761.559.590.900 430:E05.581.249 686:D27.505.954.158|ES| 2:1 18:1 19:1 32:1 60:1 75:1 103:1 113:1 115:1 321:1 399:1 658:1 796:1 953:1 1256:1 1363:1 1477:1 2795:1 3672:1 3673:1 3674:1 3675:1 3676:1
1 	|BT| (S (VP (PRP$ Our) (S (VP (VBP result) (VP (VBP demonstrate) (S (NP (JJ potential) (JJ therapeutic) (NN role) (NN panobinostat)) (VP (VBG targeting) (NP (JJ aggressive) (JJ triple-negative) (NN breast) (NN cancer) (NN cell) (NN type))))))))) |ET| |BS|15:F01.829.316.616 41:A11 52:E02 160:C04.588.180.788 162:F01.145.126.125|ES| 18:1 19:1 23:1 26:1 31:1 94:1 101:1 502:1 538:1 541:1 543:1 616:1 658:1 827:1 3348:1
1 	|BT| (NP (NP (PRP$ Our) (VP (VBP result) (VP (VBP demonstrate) (S (VP (NN resveratrol) (VP (VB potentiate) (NP (JJ anti-tumor) (NN effect) (NN 5-FU) (NN CRC) (NN cell) (NN chemosensitizing)) (, ,) (S (VP (VBG inhibiting) (NP (NNP EMT) (NN phenotype)) (PP (IN via) (NP (NN up-regulation) (JJ intercellular) (NN junction) (NN down-regulation) (NN NF-kappaB) (NN pathway)))))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 12:Z01.542.049 41:A11 80:G05.695 85:G02.111.087.225 122:C14.280.383 142:I01.880.604 210:D12.776.260.600 560:D03.383.742.698.875.404 1054:A11.284.149.165.420|ES| 2:1 19:1 75:1 94:1 101:1 236:1 245:1 257:1 383:1 502:1 596:1 658:1 714:1 880:1 896:1 1712:1 1759:1 2075:1 2308:1 3677:1 3678:1 3679:1 3680:1
1 	|BT| (FRAG (ADVP (RB Overall)) (, ,) (NP (NP (JJ 2-SeCD) (NNS sensitises) (JJ resistant) (NN breast) (NN cancer) (NN cell) (JJ TRAIL-based) (NN apoptosis)) (ADVP (FW vitro) (FW vivo)))) |ET| |BS|39:G04.299.139.160 41:A11 333:D01.045 696:V02.270.500|ES| 2:1 18:1 19:1 23:1 89:1 94:1 216:1 378:1 427:1 2858:1 3681:1 3682:1 3683:1
1 	|BT| (NP (NP (NN Overexpression) (NN 5-lipoxygenase) (NN colon) (NN polyp) (NN cancer) (NN effect) (NN 5-LOX) (NN inhibitor) (NN vitro) (JJ murine) (NN model))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 548:D08.811.682.664.500.848 1055:D08.811.682.690.416.583.625 1056:C23.300.825.411.235|ES| 18:1 19:1 72:1 75:1 113:1 216:1 380:1 627:1 647:1 668:1 3390:1 3684:1
1 	|BT| (S (NP (NP (NN Overexpression) (NN cyclooxygenase) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN COX2)) (-RRB- -RRB-))) (NP (NP (JJ uncontrolled) (JJ wingless) (NN Int) (-LRB- -LRB-) (NN Wnt) (-RRB- -RRB-) (: -)) (NN signaling) (NN pathway)) (ADVP (RB long)) (VP (VBD suggested) (NP (NP (NN play) (JJ crucial) (NN role)) (NP (JJ colorectal) (NN cancer))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 15:F01.829.316.616 24:D08.811.600.720.750 30:Z01.058.290.190.800 31:D08.811.520.224.800 79:I03.450.642.693 147:G02.149.115.800.925|ES| 10:1 14:1 17:1 18:1 19:1 31:1 148:1 238:1 383:1 668:1 877:1 925:1 2325:1 3180:1 3685:1 3686:1 3687:1 3688:1 3689:1 3690:1
1 	|BT| (S (NP (NP (NN Overexpression) (NN cyclooxygenase) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN COX-2)) (-RRB- -RRB-))) (ADVP (RB frequently)) (VP (VBD found) (NP (JJ early) (JJ advanced) (NN lung) (NN cancer)))) |ET| |BS|24:D08.811.600.720.750|ES| 10:1 14:1 18:1 19:1 37:1 76:1 148:1 328:1 668:1 698:1 997:1 1128:1 3180:1
1 	|BT| (S (NP (NN Overexpression) (NN glutamine) (NN synthetase)) (VP (VBN associated) (NP (NNS beta-catenin-mutations) (NN mouse) (NN liver) (NN tumor) (NN promotion) (NN hepatocarcinogenesis) (NN phenobarbital)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 23:D12.776.091.249 515:C04.588.274.623 756:D03.383.742.698.253.650 1057:D08.811.464.259.200.600|ES| 7:1 19:1 52:1 169:1 668:1 836:1 900:1 2337:1 2685:1 3691:1 3692:1 3693:1
1 	|BT| (S (NP (NN Pamidronate)) (VP (VBD induced) (NP (JJ anti-proliferative) (, ,) (NP (JJ apoptotic) (, ,) (NP (JJ anti-migratory) (NN effect) (JJ hepatocellular) (NN carcinoma)))))) |ET| |BS|39:G04.299.139.160 104:C04.557.470.200.025.255|ES| 2:1 19:1 75:1 303:1 304:1 412:1 2223:1 3694:1 3695:1 3696:1
1 	|BT| (S (NP (JJ Past) (NN study)) (VP (VBN shown) (VP (VBD amplified) (NP (NP (NP (JJ insulin-like) (NN growth) (NN factor) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN IGF1)) (-RRB- -RRB-))) (: /) (NP (NP (NP (NP (NN IGF1) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN IGF1-R)) (-RRB- -RRB-))) (NN signalling) (JJ important) (NN role)) (NP (NP (NP (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (NP (NN development)))) (, ,) (NP (NN progression) (NN resistance) (NN treatment)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 12:Z01.542.049 15:F01.829.316.616 16:C23.550.291.656 52:E02 518:D08.811.913.696.620.682.725.400.185 598:D12.644.276.937.400 599:M01.526.799.500|ES| 2:1 10:1 14:1 17:1 18:1 19:1 31:1 35:1 48:1 98:1 102:1 131:1 185:1 186:1 237:1 245:1 546:1 902:1 1094:1 2093:1 2198:1 2208:1 2437:1 3697:1 3698:1 3699:1
1 	|BT| (NP (NP (NNS Polymorphisms) (NP (JJ estrogen-metabolizing) (NN gene) (NN risk) (JJ hepatocellular) (NN carcinoma)) (NNP Taiwan) (NN female))) |ET| |BS|6:G05.360.340.024.340 61:E05.318.740.600.800 104:C04.557.470.200.025.255 307:G05.365.795 889:D27.505.696.399.472.277 1058:Z01.252.474.872|ES| 9:1 19:1 171:1 303:1 304:1 1404:1 3700:1 3701:1 3702:1
1 	|BT| (NP (NP (NNP Prevention) (JJ upper) (JJ aerodigestive) (NN tract) (NN cancer) (JJ zinc-deficient) (JJ rodent)) (: :) (NP (NN inefficacy) (JJ genetic) (JJ pharmacological) (NN disruption) (NN COX-2))) |ET| |BS|514:B01.050.150.900.649.865 874:D01.268.556.940 1059:H01.158.703|ES| 18:1 19:1 76:1 104:1 864:1 1602:1 2173:1 2898:1 3101:1 3703:1 3704:1 3705:1 3706:1 3707:1
1 	|BT| (S (ADVP (RB Previously)) (, ,) (VP (VBD showed) (SBAR (S (NP (JJ habitual) (JJ heavy) (NN alcohol) (NN ingestion)) (VP (VBD amplified) (S (NP (NP (JJ age-related) (NN hepatocarcinogenesis) (NN P) (NN rat)) (, ,) (NP (NP (CD 80) (NN %)) (NP (JJ alcohol-consuming) (NP (NN P) (NN rat) (VBG developing) (NNS HCCs)) (NP (CD 18) (NN month) (NN alcohol) (NN exposure)))) (, ,)) (VP (VBN compared) (NP (ADJP (CD 5) (NN %)) (NN water-drinking) (NN control))))))))) |ET| |BS|104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 751:D02.033.375 822:D02.033 904:F01.145.317.269 1060:D01.045.250.875.300|ES| 2:1 19:1 50:1 132:1 289:1 311:1 369:1 573:1 578:1 590:1 767:1 849:1 900:1 1132:1 1953:1 2208:1 2723:1 3708:1 3709:1 3710:1 3711:1 3712:1 3713:1 3714:1 3715:1
1 	|BT| (NP (NP (JJ Prognostic) (NN significance) (NN metallothionein) (JJ human) (JJ gastrointestinal) (NN cancer))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 777:D12.776.556.670|ES| 18:1 19:1 36:1 183:1 557:1 2731:1 3716:1
1 	|BT| (NP (NP (NNP Promotion) (NN hepatocarcinogenesis) (NN perfluoroalkyl) (NN acid) (NN rainbow) (NNS trout))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 1061:B01.050.150.900.493.817.750.825.580.600 1062:D01.029|ES| 19:1 900:1 1275:1 3717:1 3718:1 3719:1 3720:1
1 	|BT| (NP (NP (NP (NN Protein) (NN kinase) (NN Cbeta)) (NP (JJ effective) (NN target) (NN chemoprevention) (NN colon) (NN cancer)))) |ET| |BS|12:Z01.542.049 253:E02.319.162 867:D08.811.913.696.620.682.700.725.049|ES| 18:1 19:1 113:1 160:1 470:1 870:1 1639:1 2911:1 3721:1
1 	|BT| (S (NP (NP (NN Protein) (NN kinase) (NN CbetaII)) (PRN (-LRB- -LRB-) (NP (NN PKCbetaII)) (-RRB- -RRB-))) (VP (VP (VBP play) (NP (JJ requisite) (NN role) (NN initiation) (NN colon)) (NP (NP (NN carcinogenesis) (JJ preclinical) (NN mouse) (NN model)) (VP (VBG promoting) (NP (NN proliferation))))) (VP (VBD increased) (NP (NN beta-catenin) (NN accumulation))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 23:D12.776.091.249 33:C04.697.098 46:A03.556.124.526.356 79:I03.450.642.693 866:D08.811.913.696.620.682.700.725.049 1063:D08.811.913.696.620.682|ES| 10:1 14:1 19:1 31:1 47:1 52:1 60:1 72:1 113:1 207:1 238:1 299:1 470:1 637:1 881:1 1494:1 2120:1 2911:1 3077:1 3722:1 3723:1
-1 	|BT| (NP (NP (NN AIM) (: :)) (S (S (VP (TO To) (VP (VB elucidate) (S (NP (JJ anticancer) (NN mechanism) (NNP Huqi) (NNP San)) (VP (VBG assessing) (NP (NN expression) (NN G-6-Pase))))))) (, ,) (NP (NP (NN SDH)) (, ,) (NP (NN ATPase) (NN AFP) (JJ N-nitrosodiethylamine-mediated) (NN hepatocarcinogenesis) (NN rat))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 893:D08.811.277.040.025 894:D08.811.277.040.025|ES| 2:1 19:1 104:1 115:1 162:1 828:1 849:1 900:1 959:1 1196:1 1697:1 1880:1 2762:1 2765:1 2766:1 3630:1 3632:1 3634:1 3957:1
-1 	|BT| (S (NP (NN AIM) (: :)) (S (VP (TO To) (VP (VB investigate) (NP (NP (NP (JJ therapeutic) (NN effect) (JJ potential) (NN mechanism) (JJ natural) (NN flavonoid) (NN quercetin-3-O-beta-D-glucuronide)) (PRN (-LRB- -LRB-) (NP (NN Q3GA)) (-RRB- -RRB-))) (VP (NN lipid) (NP (NP (NN metabolism) (NN disorder) (JJ free) (JJ fatty) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN FFA)) (-RRB- -RRB-)))))))) (: -) (VP (VBN induced) (NP (NN fatty) (NN liver)) (ADVP (FW vivo) (FW vitro)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 242:A03.620 533:D03.383.663.283.266.450.284.777 534:D03.383.663.283.266.450 1132:C18.452.584 1133:D10.251.310|ES| 10:1 14:1 19:1 75:1 104:1 162:1 216:1 378:1 409:1 459:1 541:1 827:1 828:1 836:1 959:1 1275:1 1886:1 2007:1 2070:1 2333:1 2401:1 3163:1 3958:1 3959:1 3960:1 3961:1
-1 	|BT| (NP (NP (NN Alcohol) (JJ well-established) (NN risk) (NN factor) (JJ hepatocellular) (NN carcinoma)) (, ,) (NP (NN mechanism) (NN alcohol) (NN liver) (NN cancer) (NN complex))) |ET| |BS|104:C04.557.470.200.025.255 409:E05.318.740.600.800.725 751:D02.033.375 822:D02.033|ES| 2:1 18:1 19:1 162:1 171:1 185:1 303:1 304:1 695:1 836:1 1770:1 3710:1 3962:1
-1 	|BT| (NP (NP (NP (JJ Altered) (NN gene) (NN expression) (NN DNA) (NN repair)) (: -) (NP (NP (NN cell) (JJ proliferation-associated) (NNS proteins/enzymes)) (VP (VBN examined) (NP (NN process) (JJ tamoxifen-induced) (NN hepatocarcinogenesis) (JJ female) (JJ Sprague-Dawley) (NN rat)))))) |ET| |BS|155:G05.355.310 640:D02.455.426.559.389.150.700.900 642:M01.975 730:D08.811 769:B01.050.150.900.649.865.635.505.700.750 1134:G02.111.087.219 1135:D12.776.543|ES| 9:1 19:1 94:1 115:1 324:1 638:1 666:1 849:1 900:1 971:1 1404:1 2707:1 3963:1 3964:1 3965:1 3966:1
-1 	|BT| (NP (NP (NP (NN BACKGROUND)) (CC &) (NP (NNS AIMS))) (: :) (S (NP (JJ Chronic) (NN alcohol) (NN drinking)) (VP (VBZ accelerates) (NP (NP (NN liver) (NN fibrosis) (NN patient)) (JJ viral) (NN hepatitis)) (VP (ADVP (RB fully)) (VBD explained) (NP (JJ ethanol-enhanced) (NN liver) (NN damage)))))) |ET| |BS|50:M01.643 242:A03.620 676:C06.552.630 751:D02.033.375 904:F01.145.317.269 1136:B04.450|ES| 19:1 104:1 120:1 529:1 836:1 889:1 949:1 1046:1 1777:1 1778:1 1848:1 2048:1 3710:1 3967:1 3968:1 3969:1 3970:1 3971:1
-1 	|BT| (NP (NP (NN BACKGROUND) (: :)) (S (NP (NN Alcohol) (NN consumption)) (VP (VBZ promotes) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))))) |ET| |BS|104:C04.557.470.200.025.255 904:F01.145.317.269|ES| 10:1 14:1 19:1 104:1 298:1 303:1 304:1 441:1 1046:1 2387:1 3962:1
-1 	|BT| (S (NP (NP (NP (NN BACKGROUND) (: :)) (NP (NP (JJ Chemopreventive) (NN effect) (JJ selective) (NN cyclooxygenase-2)) (PRN (-LRB- -LRB-) (NP (NN COX-2)) (-RRB- -RRB-))) (NN inhibitor) (NN JTE-522) (NN diethylnitrosamine) (-LRB- -LRB-) (NN DEN) (-RRB- -RRB-) (: -)) (VBN induced) (NN hepatocarcinogenesis)) (VP (VBD evaluated) (NP (NNP Wistar) (NN rat)))) |ET| |BS|225:E05.337 349:D27.505.519.389.310.500 554:D02.654.442.200 624:D27.505.696.706.018 723:B01.050.150.900.649.865.635.505.700.900|ES| 10:1 14:1 19:1 61:1 75:1 76:1 104:1 380:1 409:1 780:1 849:1 900:1 1046:1 1749:1 1875:1 1952:1 2603:1 3972:1 3973:1
-1 	|BT| (NP (NP (NN BACKGROUND) (: :)) (NP (JJ Chronic) (NP (NP (NN ethanol) (NN consumption) (NN increase) (NN risk) (JJ hepatic) (NN cirrhosis) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))) |ET| |BS|61:E05.318.740.600.800 104:C04.557.470.200.025.255 357:C06.552.630 904:F01.145.317.269|ES| 10:1 14:1 19:1 40:1 104:1 171:1 303:1 304:1 441:1 838:1 1046:1 1199:1 2387:1 3440:1 3967:1
-1 	|BT| (NP (NP (NN BACKGROUND) (: :)) (S (NP (NP (JJ Hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (ADVP (RB rapidly)) (VP (VBG increasing) (NP (NP (NN cancer)) (WHNP (WHNP (WP$ whose) (JJ known) (NN risk) (NN factor)) (NP (JJ chronic) (NN ethanol) (NN abuse))) (, ,) (NP (JJ viral) (NN hepatitis) (NN infection)) (, ,) (NP (NN aflatoxin) (NN exposure)))))) |ET| |BS|104:C04.557.470.200.025.255 409:E05.318.740.600.800.725 1137:D03.383.663.283.119 1138:C02.440.420 1139:C25.775.100.250 1140:C06.552.380 1141:C02|ES| 2:1 10:1 14:1 18:1 19:1 104:1 171:1 185:1 304:1 441:1 556:1 715:1 919:1 1046:1 1790:1 1953:1 2048:1 2151:1 2214:1 2362:1 3424:1 3440:1 3969:1 3974:1
-1 	|BT| (NP (NP (NP (NN BACKGROUND)) (: :) (NP (NP (JJ Prolonged) (JJ high) (NN intake) (JJ dietary) (NN selenium)) (VP (VBN shown) (VP (VBP induce) (NP (JJ gestational) (NN diabetes) (NN rat) (NN hyperinsulinemia) (NN pig))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 595:G07.203.650.240 935:D01.268.185.850 1053:C18.452.394.968 1142:B01.050.150.900.649.077.880.399 1143:B01.050.150.900.649.077.880 1144:C13.703.170|ES| 19:1 104:1 178:1 237:1 243:1 849:1 1046:1 2009:1 2563:1 2594:1 3284:1 3670:1 3975:1 3976:1 3977:1
-1 	|BT| (S (NP (NP (NP (JJ Carcinogenic) (NN risk) (JJ molecular) (NN mechanism)) (VP (VBG underlying) (NP (NP (NN liver) (JJ tumor-promoting) (NN activity)) (NN copper) (NN gluconate)))) (, ,) (NP (JJ additive) (JJ functional) (NN food)) (, ,)) (VP (VBN investigated) (S (VP (VBG using) (NP (NP (NP (NN rat) (JJ medium-term) (NN liver) (NN carcinogenicity) (NN bioassay) (NN protocol)) (PRN (-LRB- -LRB-) (NP (NN Ito) (NN test)) (-RRB- -RRB-))) (ADJP (ADJP (JJ 2-week)) (ADJP (JJ short-term))) (NN administration) (NN experiment)))))) |ET| |BS|12:Z01.542.049 61:E05.318.740.600.800 106:E05.091 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 515:C04.588.274.623 849:G08.686.785.760.769.490.500 914:L01.178 1145:D02.241.081.844.322 1146:D27.720.368 1147:C17.800.621|ES| 2:1 10:1 14:1 19:1 161:1 162:1 171:1 350:1 399:1 403:1 415:1 435:1 836:1 849:1 1418:1 2470:1 2575:1 2632:1 2931:1 3022:1 3215:1 3216:1 3266:1 3583:1 3776:1 3801:1 3978:1 3979:1 3980:1 3981:1
-1 	|BT| (NP (NP (JJ Chronic) (JJ excessive) (NN alcohol) (NN consumption) (NN lead) (NN development)) (NP (NP (JJ alcoholic) (NN liver) (NN disease)) (PRN (-LRB- -LRB-) (NP (NN ALD)) (-RRB- -RRB-))) (S (VP (ADVP (RB greatly)) (VB increase) (NP (NN risk) (NN liver) (NN cancer))))) |ET| |BS|61:E05.318.740.600.800 86:D01.268.556.435 650:C06.552 904:F01.145.317.269 1148:M01.066|ES| 10:1 14:1 18:1 19:1 35:1 40:1 171:1 254:1 836:1 998:1 2387:1 2880:1 3710:1 3967:1 3982:1 3983:1 3984:1
-1 	|BT| (S (NP (JJ Chronic) (NN exposure) (NN toxaphene)) (VP (VBD resulted) (NP (NN increase) (NN liver) (NN tumor) (NN B6C3F1) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 515:C04.588.274.623 1149:D02.455.526.439.913|ES| 7:1 19:1 40:1 52:1 594:1 836:1 1953:1 3967:1 3985:1 3986:1
-1 	|BT| (SINV (NP (NP (JJ Hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NP (CD one) (JJ common) (NN cancer)) (ADVP (RB worldwide)) (, ,) (VP (VBD caused)) (NP (NP (NP (NNP Hepatitis) (NNP C) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN HCV)) (-RRB- -RRB-))) (NN hepatotoxin))) |ET| |BS|104:C04.557.470.200.025.255 550:B04.450.410|ES| 2:1 10:1 14:1 18:1 19:1 304:1 441:1 655:1 1010:1 1422:1 1938:1 1954:1 1955:1 2151:1 2506:1 3987:1 3988:1
-1 	|BT| (NP (NP (NP (NN Mouse) (JJ nongenotoxic) (NNS hepatocarcinogens)) (SBAR (S (NP (JJ phenobarbital) (PRN (-LRB- -LRB-) (NP (NN PB)) (-RRB- -RRB-)) (NN chlordane)) (VP (VBP induce) (ADVP (RB hepatomegaly)) (VP (VBN characterized) (NP (NN hypertrophy) (NN hyperplasia)))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 510:C23.550.444 756:D03.383.742.698.253.650 1150:D02.455.526.439.180 1151:C06.552.416 1152:C23.300.775|ES| 10:1 14:1 19:1 243:1 985:1 1795:1 2127:1 2685:1 3340:1 3496:1 3989:1 3990:1 3991:1 3992:1
-1 	|BT| (NP (NP (NP (NNS OBJECTIVES)) (: :) (NP (NP (NP (NP (DT The) (JJ chemopreventive) (JJ potential) (NN Tephrosia) (NN purpurea) (NN extract)) (PRN (-LRB- -LRB-) (NP (NN TPE)) (-RRB- -RRB-))) (NN N-nitrosodiethylamine) (-LRB- -LRB-) (NN NDEA) (-RRB- -RRB-) (: -)) (VP (VBN induced) (NP (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (SBAR (S (NP (JJ Wistar) (NN rat)) (VP (VBN assessed))))))))) |ET| |BS|104:C04.557.470.200.025.255 415:F01.658.500 554:D02.654.442.200 723:B01.050.150.900.649.865.635.505.700.900 1153:B01.650.940.800.575.100.401.890|ES| 10:1 14:1 19:1 104:1 303:1 304:1 409:1 441:1 691:1 827:1 849:1 1946:1 2496:1 2602:1 2603:1 3823:1 3993:1 3994:1 3995:1 3996:1 3997:1
-1 	|BT| (S (NP (PRP$ Our) (JJ prior) (NN work)) (VP (VBD showed) (NP (NP (NP (JJ brief) (NN exposure) (JJ pregnant) (NN C3H) (NN mouse) (JJ inorganic) (JJ arsenic-induced) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NP (NN formation) (JJ adult) (JJ male) (NN offspring))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 445:I03.946 1154:B01.050.050.199.520.520.388 1155:G08.686.340 1156:F01.829.263.065 1157:E05.916.039 1158:D01.268.513.249|ES| 10:1 14:1 19:1 43:1 52:1 132:1 303:1 304:1 355:1 441:1 658:1 1402:1 1546:1 1953:1 3174:1 3998:1 3999:1 4000:1 4001:1 4002:1 4003:1
-1 	|BT| (NP (NP (NP (NNP Phenobarbital)) (PRN (-LRB- -LRB-) (NP (NN PB)) (-RRB- -RRB-))) (NP (NP (NP (NN orphenadrine) (-LRB- -LRB-) (NN ORPH) (-RRB- -RRB-) (NN cytochrome) (NN P450)) (PRN (-LRB- -LRB-) (NP (NN CYP)) (-RRB- -RRB-))) (NP (NN 2B) (NN inducer) (NN liver) (JJ tumor-promoting) (NN effect) (NN rat)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 756:D03.383.742.698.253.650 1159:D02.092.471.600 1160:D27.505.389.249|ES| 10:1 14:1 19:1 75:1 836:1 849:1 2549:1 3496:1 3776:1 3788:1 3789:1 3791:1 4004:1 4005:1 4006:1 4007:1
-1 	|BT| (S (NP (NN Rat) (NN liver) (NN tumor)) (VP (VBD initiated) (NP (NP (NP (NN N-nitrosodiethylamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (VP (VBD followed) (S (NP (NP (NN promotion) (NN phenobarbital)) (PRN (-LRB- -LRB-) (NP (NN PB)) (-RRB- -RRB-))) (NP (NP (NP (VBN examined) (NN expression) (VBG transforming) (NN growth) (NN factor-beta)) (PRN (-LRB- -LRB-) (NP (NN TGF) (NN beta)) (-RRB- -RRB-))) (NP (NN type) (CD I) (, ,) (NP (QP (CD II) (CD III))) (NP (NN receptor))))))))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 554:D02.654.442.200 756:D03.383.742.698.253.650 1161:D12.644.276.374.687.100|ES| 2:1 7:1 10:1 14:1 19:1 102:1 115:1 186:1 324:1 543:1 836:1 1116:1 1772:1 1773:1 1875:1 1900:1 1972:1 2281:1 2337:1 2350:1 2602:1 2685:1 3130:1 3496:1 4008:1 4009:1
-1 	|BT| (S (NP (NP (DT The) (JJ key) (NN event) (JJ responsible) (NN mouse) (NN liver) (NN tumor)) (VP (VBD induced) (NP (NP (NN pesticide)) (PRN (-LRB- -LRB-) (NP (NP (NN viz.)) (, ,) (NP (NN pronamide))) (-RRB- -RRB-))))) (VP (VBD investigated) (NP (S (NP (NN series) (NN study)) (VP (VBG employing) (ADJP (ADJP (JJ molecular)) (, ,) (ADJP (JJ biochemical)) (, ,) (ADJP (JJ cellular))))) (, ,) (NP (JJ apical) (NN endpoint))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 41:A11 515:C04.588.274.623 913:D27.720.031.700|ES| 2:1 7:1 10:1 14:1 19:1 52:1 131:1 159:1 161:1 205:1 403:1 412:1 691:1 836:1 1689:1 1807:1 2132:1 3074:1 3214:1 3323:1 4010:1 4011:1 4012:1 4013:1
-1 	|BT| (S (NP (DT The) (JJ objective) (NN study)) (VP (VBD determine) (SBAR (S (NP (NP (NP (NP (JJ chemopreventive) (NN activity) (JJ Korean) (JJ red) (NN ginseng) (NN extract)) (PRN (-LRB- -LRB-) (NP (NN KRG)) (-RRB- -RRB-))) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (VP (VBD induced) (NP (NN hepatocarcinogenesis) (NN rat))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 415:F01.658.500 554:D02.654.442.200 1162:B01.650.940.800.575.100.087.500|ES| 10:1 14:1 19:1 74:1 131:1 399:1 412:1 691:1 849:1 900:1 1634:1 1875:1 1946:1 1952:1 2496:1 2916:1 4014:1 4015:1 4016:1
-1 	|BT| (S (NP (DT The) (JJ present) (NN study)) (VP (VBN designed) (VP (VB determine) (SBAR (IN whether) (S (NP (NN alteration) (NN expression) (NN RXRalpha) (NN retinoid) (NN receptor) (NN RARalpha) (NN RARbeta)) (VP (VBN involved) (NP (NP (NN hepatocarcinogenesis)) (VP (VBG using) (NP (NP (NP (CD 3) ('' ') (: -) (NN methyl-4-dimethylaminoazobenzene) (-LRB- -LRB-) (CD 3) ('' ') (: -)) (NP (NN MeDAB) (-RRB- -RRB-) (: -))) (VP (VBN induced) (NP (NN rat) (NN liver) (NN carcinogenesis) (NN model)))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 1163:D02.092.146.325.500 1164:D12.776.826.701|ES| 10:1 14:1 19:1 72:1 74:1 115:1 131:1 186:1 207:1 221:1 350:1 409:1 691:1 774:1 836:1 849:1 900:1 951:1 1307:1 1683:1 2573:1 4017:1 4018:1 4019:1 4020:1 4021:1
-1 	|BT| (S (NP (NP (DT The) (JJ present) (NN study)) (VP (VBN undertaken))) (VBP investigate) (NP (NP (NN effect) (JJ dietary) (NN supplementation) (NN nimesulide) (NN eugenol) (NN N-nitrosodiethylamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (VP (VBN initiated) (NP (JJ early) (NN hepatocarcinogenesis) (NN F344) (JJ male) (NN rat)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 554:D02.654.442.200 590:B01.050.050.199.520.760.200 595:G07.203.650.240 1165:D02.241.223.200.054.500|ES| 10:1 14:1 19:1 75:1 131:1 459:1 691:1 849:1 900:1 1128:1 1307:1 1402:1 1875:1 2567:1 2594:1 2602:1 3185:1 3186:1 4022:1 4023:1 4024:1
-1 	|BT| (S (NP (NP (DT The) (JJ preventive) (NN effect)) (VP (VP (VBN processed) (NP (NP (NP (NP (NNP Aloe) (NN vera) (NN gel)) (PRN (-LRB- -LRB-) (NP (NN PAG)) (-RRB- -RRB-))) (NN colon) (NN carcinogenesis)) (VP (VBN examined) (S (VP (VBG using) (NP (NP (NN azoxymethane)) (PRN (-LRB- -LRB-) (NP (NN AOM)) (-RRB- -RRB-)))))))) (: -) (VP (VBN initiated) (NP (NP (NN dextran) (NN sodium) (NN sulfate)) (PRN (-LRB- -LRB-) (NP (NN DSS)) (-RRB- -RRB-)))))) (: -) (VP (VBD promoted) (NP (NN mouse) (NN colon) (NN carcinogenesis) (NN model)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 131:D09.698.365.272.300 132:D02.172.080|ES| 10:1 14:1 19:1 52:1 72:1 75:1 113:1 207:1 324:1 350:1 406:1 407:1 674:1 691:1 1883:1 1993:1 1994:1 3300:1 3306:1 4024:1 4025:1 4026:1 4027:1 4028:1 4029:1
-1 	|BT| (S (NP (NP (NP (DT The) (NN process) (NN hepatocarcinogenesis) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (JJ initiation/phenobarbital) (-LRB- -LRB-) (NN PB) (-RRB- -RRB-) (NN promotion) (NN mouse) (NN model)) (VP (VBZ involves) (NP (NP (JJ selective) (JJ clonal) (NN outgrowth) (NN cell) (NN harboring) (NN oncogene) (NN mutation) (NN Ctnnb1)) (, ,) (S (NP (JJ spontaneous) (JJ DEN-only-induced) (NN tumor)) (ADVP (RB often)) (NP (NP (NN Ha-ras)) (: -) (NP (JJ B-raf-mutated))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 9:G05.360.340.024.340.375.500 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 23:D12.776.091.249 41:A11 216:Z01.107.084.900.425 278:D08.811.913.696.620.682.700.559.842.374 301:A11.251.353 554:D02.654.442.200 756:D03.383.742.698.253.650|ES| 2:1 7:1 10:1 14:1 19:1 24:1 34:1 52:1 72:1 94:1 283:1 632:1 638:1 691:1 900:1 1069:1 1304:1 1673:1 1749:1 1875:1 1952:1 2337:1 3496:1 4030:1 4031:1 4032:1 4033:1 4034:1 4035:1
-1 	|BT| (S (NP (NP (NP (DT The) (JJ tumour-promoting) (NN effect) (NN beta-naphthoflavone)) (PRN (-LRB- -LRB-) (NP (NN BNF)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (JJ novel) (NN aryl) (NN hydrocarbon) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN AhR)) (-RRB- -RRB-))) (NN agonist)) (, ,)) (VP (VBN investigated) (S (VP (VBG using) (NP (JJ medium-term) (NN hepatocarcinogenesis) (NN model) (NN rat)))))) |ET| |BS|8:C04 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 259:D12.776.395.240.150.500 849:G08.686.785.760.769.490.500 914:L01.178 969:D12.776.260.643.715 983:D03.383.663.283.266.450.175.100|ES| 2:1 10:1 14:1 19:1 72:1 75:1 186:1 350:1 403:1 691:1 849:1 891:1 900:1 3215:1 3228:1 3417:1 3418:1 3468:1 4036:1 4037:1 4038:1
-1 	|BT| (S (NP (EX There)) (NP (JJ abundant) (JJ epidemiological) (NN evidence) (JJ heavy) (NN alcohol) (NN intake)) (VP (VBZ contributes) (NP (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN development)))) |ET| |BS|104:C04.557.470.200.025.255 651:H02.403.720.500 904:F01.145.317.269|ES| 10:1 14:1 19:1 35:1 38:1 303:1 304:1 441:1 767:1 845:1 1798:1 2563:1 3217:1 3710:1 4039:1
-1 	|BT| (S (NP (DT This) (NN study)) (VP (VBZ validates) (NP (NP (NP (NN utility) (NN Gum) (JJ Arabic-conjugated) (NN gold) (NNS nanoparticles)) (PRN (-LRB- -LRB-) (NP (NNS GA-AuNPs)) (-RRB- -RRB-))) (SBAR (S (NP (NN laser)) (VP (VBP induce) (NP (JJ photothermal) (NN inhibition) (NN hepatocarcinogenesis)))))) (, ,) (PP (IN via) (S (VP (VBG employing) (NP (NP (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-)))))) (FRAG (: -) (NP (VBN mediated) (JJ hepatocellular) (NN carcinoma) (NN model))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 104:C04.557.470.200.025.255 554:D02.654.442.200 1166:Z01.058.290.190.300 1167:D05.750.078.739.500 1168:J01.637.512.600 1169:D01.268.556.322 1170:E07.632.490|ES| 2:1 10:1 14:1 19:1 72:1 103:1 131:1 243:1 303:1 304:1 596:1 807:1 900:1 1875:1 1952:1 2194:1 4011:1 4040:1 4041:1 4042:1 4043:1 4044:1 4045:1 4046:1 4047:1 4048:1
-1 	|BT| (NP (NP (S (VP (TO To) (VP (VB clarify) (S (VP (VBG modifying) (NP (NP (NN effect) (NN N-Acetyl-L-Cysteine)) (PRN (-LRB- -LRB-) (NP (NN NAC)) (-RRB- -RRB-)))))))) (, ,) (NP (NP (JJ antioxidative) (NN ability)) (, ,) (NP (NN hepatocarcinogenesis)) (VP (VBD promoted) (SBAR (S (NP (NP (NP (NP (NN fenofibrate)) (PRN (-LRB- -LRB-) (NP (NN FF)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NN peroxisome) (JJ proliferator-activated) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN PPAR)) (-RRB- -RRB-))) (NN alpha)) (NP (NN agonist))) (, ,) (NP (NP (JJ male) (NN F344/N) (NN rat)) (VP (VBN administered) (NP (NP (NP (ADJP (JJ single) (JJ intraperitoneal)) (NN injection) (NN N-diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (NN initiator))))) (VP (VBD followed) (NP (NN administration) (NN diet) (VBG containing) (CD 3,000) (NN ppm) (NN FF) (CD 16) (NN week))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 385:F02.784.629.131 536:D12.776.826.239.500 554:D02.654.442.200 590:B01.050.050.199.520.760.200 596:E02.642.249 791:D02.886.030.230.259 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725 916:D02.241.081.114.968.500.625 917:E02.319.267.530.490|ES| 2:1 10:1 14:1 19:1 75:1 186:1 286:1 783:1 785:1 828:1 849:1 900:1 1300:1 1402:1 1801:1 1836:1 1875:1 1887:1 1912:1 2191:1 2336:1 2575:1 2644:1 2846:1 3130:1 3193:1 3221:1 3222:1 3223:1 3224:1 3225:1 3226:1 3227:1 3228:1 3229:1 3230:1 3231:1 3232:1 3233:1 3234:1
-1 	|BT| (S (VP (TO To) (VP (VB clarify) (NP (NP (JJ possible) (NN mechanism) (JJ non-genotoxic) (NN hepatocarcinogenesis)) (VP (VBD induced) (NP (NP (NP (NN piperonyl) (NN butoxide)) (PRN (-LRB- -LRB-) (NP (NN PBO)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ male) (NN F344) (NN rat)) (VP (VBN administered) (S (NP (NN i.p))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 590:B01.050.050.199.520.760.200 967:D01.248.497.158.490 1077:D03.383.246.118.600|ES| 2:1 10:1 14:1 19:1 162:1 412:1 828:1 849:1 900:1 1359:1 1402:1 2336:1 3185:1 3193:1 3777:1 3778:1 4049:1 4050:1 4051:1
-1 	|BT| (S (S (VP (TO To) (VP (VB investigate) (NP (NP (NP (JJ protective) (NN effect) (NN bilberry) (NN extract)) (PRN (-LRB- -LRB-) (NP (NN BBE)) (-RRB- -RRB-))) (NP (NP (NP (ADJP (RB enzymatically) (VBN modified)) (NN isoquercitrin)) (PRN (-LRB- -LRB-) (NP (NN EMIQ)) (-RRB- -RRB-))) (NP (NP (JJ hepatocarcinogenic) (NN process)) (VP (VBG involving) (NP (NP (JJ oxidative) (NN stress) (NN response)) (, ,) (VP (VBN used) (S (NP (NP (JJ two-stage) (NN hepatocarcinogenesis) (NN model) (JJ N-diethylnitrosamine-initiated) (NN piperonyl) (NN butoxide)) (PRN (-LRB- -LRB-) (NP (NN PBO)) (-RRB- -RRB-))))))))))))) (: -) (VP (VBD promoted) (NP (NN rat)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 716:G03.495.710 1077:D03.383.246.118.600|ES| 2:1 10:1 14:1 19:1 72:1 75:1 459:1 476:1 493:1 494:1 638:1 828:1 849:1 900:1 2335:1 2372:1 2496:1 2522:1 2583:1 2971:1 3773:1 3774:1 3777:1 3778:1 4029:1 4050:1 4052:1 4053:1 4054:1 4055:1 4056:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (SBAR (S (NP (NN effect) (NN liver) (NN damage)) (VP (VBD induced) (NP (NN flutamide) (JJ primary) (NN rat) (NNS hepatocytes)) (S (VP (VBG using) (NP (NP (NN liver)) (NP (JJ microfluidic) (NN biochip)))))))))) |ET| |BS|242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 262:A11.436.348 1171:E05.830.666 1172:D02.065.199.420|ES| 19:1 75:1 344:1 350:1 403:1 412:1 836:1 843:1 849:1 894:1 1848:1 4057:1 4058:1 4059:1
-1 	|BT| (NP (NP (JJ 2-Amino-1-methyl-6-phenylimidazo) (PRN (-LRB- -LSB-) (ADJP (JJ 4,5-b)) (-RRB- -RSB-)) (NN pyridine) (NN increase) (NN number) (NN tumor)) (, ,) (NP (JJ cystic) (NN crypt) (JJ aberrant) (NN crypt) (NN focus) (JJ multiple) (JJ intestinal) (NN neoplasia) (NN mouse))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 102:C04.588.274.476.411 555:C04.182 744:D03.383.725 824:C04.834.020|ES| 2:1 7:1 19:1 40:1 52:1 109:1 640:1 646:1 649:1 1373:1 1378:1 1431:1 1725:1 2639:1 2640:1 2913:1 4060:1 4061:1
-1 	|BT| (S (NP (NP (JJ 2-Nitrobenzo) (-LRB- -LSB-) (-RRB- -RSB-) (NN pyrene) (NN 6-nitrochrysene)) (VP (VBD induced) (NP (NP (JJ high) (NN incidence) (NN liver) (NN tumor)) (PRN (-LRB- -LRB-) (NP (CD 91-100) (NN %)) (-RRB- -RRB-))) (, ,) (PP (VBG remaining) (NP (NN test) (NN compound))))) (VP (VBP induce) (NP (NN tumor) (NN rate)) (NP (RB significantly) (JJR higher) (JJ solvent) (NN control)))) |ET| |BS|8:C04 434:E05.318.308.985.525.375 515:C04.588.274.623 1173:D02.455.426.559.847.799 1174:D27.720.844|ES| 2:1 7:1 10:1 14:1 19:1 41:1 124:1 170:1 178:1 243:1 289:1 369:1 412:1 836:1 1373:1 1378:1 1418:1 1511:1 2433:1 4062:1 4063:1 4064:1 4065:1 4066:1 4067:1
-1 	|BT| (S (NP (DT A) (JJ diethylnitrosamine-induced) (NN liver) (NN cancer) (NN model)) (VP (VBD used) (VP (VB evaluate) (NP (NN role) (NN Myc) (NN hepatocarcinogenesis))))) |ET| |BS|15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 225:E05.337 554:D02.654.442.200|ES| 18:1 19:1 31:1 69:1 72:1 476:1 836:1 890:1 900:1 1786:1 2732:1
-1 	|BT| (S (ADVP (RB Additionally)) (, ,) (VP (VBD reported) (SBAR (S (NP (NN tamoxifen)) (VP (MD may) (VP (VB cause) (NP (NP (NP (JJ non-alcoholic) (NN fatty) (NN liver) (NN disease)) (PRN (-LRB- -LRB-) (NP (NN NAFLD)) (-RRB- -RRB-))) (NP (JJ human) (JJ experimental) (NN animal))))))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 577:C06.552.241.519 640:D02.455.426.559.389.150.700.900 1175:B01.050.050.199|ES| 2:1 10:1 14:1 19:1 36:1 46:1 263:1 491:1 836:1 993:1 998:1 1779:1 2069:1 2070:1 2371:1 2609:1 4068:1
-1 	|BT| (S (NP (NP (NP (NNP Administration) (NN acetaminophen) (NN Jnk)) (PRN (-LRB- -LRB-) (NP (NN Deltahepa)) (-RRB- -RRB-))) (NN mouse)) (VP (VBD produced) (NP (NP (JJR greater) (NN level) (NN liver) (NN injury)) (VBN observed) (NP (NP (NN Jnk1)) (PRN (-LRB- -LRB-) (NP (NN Deltahepa)) (-RRB- -RRB-))) (NN control) (NN mouse)) (, ,) (NP (VBN based) (NN level) (NN serum) (NN marker) (JJ microscopic) (JJ histologic) (NN analysis) (NN liver) (NN tissue)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 98:A10 242:A03.620 333:D01.045 426:E01.370.350.515 661:D02.065.199.092.040 1176:D23.101|ES| 2:1 10:1 14:1 19:1 52:1 134:1 249:1 261:1 272:1 289:1 534:1 661:1 836:1 1992:1 2204:1 2346:1 2412:1 2414:1 2415:1 2416:1 2741:1 4069:1 4070:1 4071:1
-1 	|BT| (FRAG (PP (IN After) (NP (NP (JJ 3-month) (NN recovery) (NN period) (JJ tamoxifen-treated) (NN rat) (JJ large) (NN liver) (NN tumor)) (PRN (-LRB- -LRB-) (NP (NN diameter) (CD 3) (NN cm)) (-RRB- -RRB-))))) |ET| |BS|8:C04 52:E02 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 640:D02.455.426.559.389.150.700.900 776:G01.910.645 1151:C06.552.416|ES| 7:1 10:1 14:1 19:1 836:1 849:1 862:1 1408:1 1409:1 2722:1 2724:1 2725:1 3265:1 4072:1 4073:1
-1 	|BT| (S (NP (NN AIRmax)) (ADVP (RB also)) (NP (JJ susceptible) (NN AIRmin) (NN colon) (NN cancer)) (VP (VP (VBD induced) (NP (NP (QP (CD 2) (CD 7)) (JJ weekly) (NNS dos)) (ADJP (ADJP (JJ 1,2-dimethylhydrazine)) (PRN (-LRB- -LRB-) (NP (NN DMH)) (-RRB- -RRB-)))) (, ,) (S (VP (VBG showing) (NP (NP (ADJP (RB significantly) (JJR higher)) (NN number) (JJ colonic) (JJ aberrant) (NN crypt) (NN focus)) (PRN (-LRB- -LRB-) (NP (NN ACF)) (-RRB- -RRB-))) (NP (CD 150) (NN day) (NN DMH) (NN treatment))))) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.01)))) (-RRB- -RRB-))) (NP (ADJP (RB significantly) (JJR higher)) (NN number) (NN tumor) (VBG affecting) (NP (NP (JJR larger) (JJ intestinal) (NN area)) (CD 300-475) (NN day)))) |ET| |BS|8:C04 46:A03.556.124.526.356 52:E02 292:Z01 433:F01.470.047 824:C04.834.020 1177:A03.556.124.526|ES| 2:1 5:1 7:1 10:1 14:1 18:1 19:1 109:1 113:1 124:1 148:1 170:1 311:1 315:1 412:1 546:1 581:1 646:1 677:1 899:1 988:1 1431:1 1725:1 2201:1 2530:1 2642:1 2643:1 2653:1 2913:1 2914:1 4074:1 4075:1 4076:1 4077:1 4078:1 4079:1 4080:1 4081:1
-1 	|BT| (NP (NP (NN Amelioration) (JJ free) (NN fatty) (JJ acid-induced) (NN fatty) (NN liver) (NN quercetin-3-O-beta-D-glucuronide) (NN modulation) (NN peroxisome) (JJ proliferator-activated) (JJ receptor-alpha/sterol) (JJ regulatory) (JJ element-binding) (JJ protein-1c) (NN signaling))) |ET| |BS|69:G02.111.087.800 242:A03.620 533:D03.383.663.283.266.450.284.777 536:D12.776.826.239.500 576:D12.776.260.103.500.750.500 1133:D10.251.310|ES| 19:1 195:1 836:1 1801:1 1817:1 1887:1 1945:1 2070:1 2599:1 3958:1 3960:1 4082:1 4083:1 4084:1 4085:1
-1 	|BT| (NP (JJ Arsenic) (VP (VBN induced) (NP (NP (NP (JJ dose-related) (NN increase) (NN lung) (NN adenocarcinoma)) (PRN (-LRB- -LRB-) (NP (NN sex)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN sex)) (-RRB- -RRB-))) (, ,) (NP (NP (NN gallbladder) (NN tumor)) (PRN (-LRB- -LRB-) (NP (NN male)) (-RRB- -RRB-))) (, ,) (NP (JJ uterine) (NN carcinoma))))) |ET| |BS|104:C04.557.470.200.025.255 265:C04.557.470.200 1158:D01.268.513.249 1178:F01.145.802.188 1179:F01.393.446.250 1180:F01.145.802 1181:G08.686.810 1182:C04.588.274.120.401 1183:A05.360.319.679|ES| 2:1 7:1 10:1 14:1 19:1 40:1 255:1 303:1 304:1 328:1 412:1 1402:1 4086:1 4087:1 4088:1 4089:1 4090:1
-1 	|BT| (S (NP (NN beta-Naphthoflavone)) (VP (VBZ enhances) (NP (NP (JJ oxidative) (NN stress) (NN response)) (NN induction) (JJ preneoplastic) (NN lesion) (JJ diethylnitrosamine-initiated) (NN hepatocarcinogenesis) (NN model)) (ADVP (RB partially)) (VP (VBD hepatectomized) (NP (NN rat))))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 716:G03.495.710 983:D03.383.663.283.266.450.175.100|ES| 19:1 72:1 494:1 736:1 849:1 900:1 1131:1 1351:1 1356:1 1438:1 2522:1 2583:1 4091:1 4092:1 4093:1
-1 	|BT| (NP (NP (NN Cell) (NN expression) (NN pattern) (NN CD147) (JJ N-diethylnitrosamine/phenobarbital-induced) (NN mouse) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 41:A11 104:C04.557.470.200.025.255 554:D02.654.442.200 756:D03.383.742.698.253.650|ES| 19:1 52:1 115:1 260:1 303:1 304:1 4094:1 4095:1 4096:1
-1 	|BT| (S (S (NP (NN Cell) (NN proliferation) (NN hepatocarcinogenesis) (NN rat)) (VP (VBD initiated) (SBAR (S (NP (NN diethylnitrosamine)) (VP (VBD promoted) (NP (NN phenobarbital))))))) (: :) (NP (NP (JJ potential) (NN role) (JJ early) (NN DNA) (NN damage) (NN liver) (NN metallothionein) (NN expression)))) |ET| |BS|15:F01.829.316.616 183:G04.299.233.750 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 526:G05.355.180 554:D02.654.442.200 756:D03.383.742.698.253.650 777:D12.776.556.670|ES| 19:1 31:1 104:1 115:1 299:1 666:1 827:1 836:1 849:1 900:1 1128:1 1848:1 1900:1 1912:1 1952:1 2685:1 2731:1 4094:1
-1 	|BT| (NP (NP (NNP Chemoprevention) (NNP Diethylnitrosamine-Initiated) (NNP Phenobarbital-Promoted) (NNP Hepatocarcinogenesis) (NNP Rats) (NNP Sulfated) (NNP Polysaccharides) (NNP Aqueous) (NN Extract) (NNP Ulva) (NN lactuca))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 253:E02.319.162 554:D02.654.442.200 756:D03.383.742.698.253.650 803:D01.248.497.158.845 804:D09.698 1184:B01.650.940.150.900|ES| 19:1 1959:1 2842:1 3664:1 4097:1 4098:1 4099:1 4100:1 4101:1 4102:1 4103:1 4104:1
